185 related articles for article (PubMed ID: 15900607)
1. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.
Madjd Z; Spendlove I; Pinder SE; Ellis IO; Durrant LG
Int J Cancer; 2005 Nov; 117(2):248-55. PubMed ID: 15900607
[TBL] [Abstract][Full Text] [Related]
2. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis.
Redondo M; García J; Villar E; Rodrigo I; Perea-Milla E; Serrano A; Morell M
Hum Pathol; 2003 Dec; 34(12):1283-9. PubMed ID: 14691914
[TBL] [Abstract][Full Text] [Related]
3. Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer.
McEvoy CR; Seshadri R; Morley AA; Firgaira FA
Tissue Antigens; 2002 Sep; 60(3):235-43. PubMed ID: 12445306
[TBL] [Abstract][Full Text] [Related]
4. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.
Wintzer HO; Benzing M; von Kleist S
Br J Cancer; 1990 Aug; 62(2):289-95. PubMed ID: 2201398
[TBL] [Abstract][Full Text] [Related]
5. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.
Madjd Z; Parsons T; Watson NF; Spendlove I; Ellis I; Durrant LG
Breast Cancer Res; 2005; 7(5):R780-7. PubMed ID: 16168124
[TBL] [Abstract][Full Text] [Related]
6. Expression of HLA class I molecules assembled with structural variants of human beta2-microglobulin.
Trymbulak WP; Zeff RA
Immunogenetics; 1997; 46(5):418-26. PubMed ID: 9271632
[TBL] [Abstract][Full Text] [Related]
7. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.
Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570
[TBL] [Abstract][Full Text] [Related]
8. Comparative assessment of MHC antigen expression in bladder and testis tumour biopsies and established urological tumour cell lines: the relevance of cytokine and gene transfection for correction of defective MHC antigens.
Nouri AM; Symes MO
Oncol Rep; 2000; 7(5):959-64. PubMed ID: 10948322
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer.
Chen HL; Gabrilovich D; Virmani A; Ratnani I; Girgis KR; Nadaf-Rahrov S; Fernandez-Viña M; Carbone DP
Int J Cancer; 1996 Sep; 67(6):756-63. PubMed ID: 8824545
[TBL] [Abstract][Full Text] [Related]
10. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.
Korkolopoulou P; Kaklamanis L; Pezzella F; Harris AL; Gatter KC
Br J Cancer; 1996 Jan; 73(2):148-53. PubMed ID: 8546899
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of HLA class I antigens in breast cancer: association with prognosis.
Gudmundsdóttir I; Gunnlaugur Jónasson J; Sigurdsson H; Olafsdóttir K; Tryggvadóttir L; Ogmundsdóttir HM
Int J Cancer; 2000 Nov; 89(6):500-5. PubMed ID: 11102894
[TBL] [Abstract][Full Text] [Related]
12. Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains.
Höglund P; Glas R; Ménard C; Kåse A; Johansson MH; Franksson L; Lemmonier F; Kärre K
Eur J Immunol; 1998 Jan; 28(1):370-8. PubMed ID: 9485216
[TBL] [Abstract][Full Text] [Related]
13. Investigation of HLA class I downregulation in breast cancer by RT-PCR.
Palmisano GL; Pistillo MP; Capanni P; Pera C; Nicolò G; Salvi S; Perdelli L; Pasciucco G; Ferrara GB
Hum Immunol; 2001 Feb; 62(2):133-9. PubMed ID: 11182222
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of MICA on high-grade invasive operable breast carcinoma.
Madjd Z; Spendlove I; Moss R; Bevin S; Pinder SE; Watson NF; Ellis I; Durrant LG
Cancer Immun; 2007 Oct; 7():17. PubMed ID: 17948965
[TBL] [Abstract][Full Text] [Related]
15. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients.
Zia A; Schildberg FW; Funke I
Int J Cancer; 2001 Aug; 93(4):566-70. PubMed ID: 11477561
[TBL] [Abstract][Full Text] [Related]
16. Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells.
Wang Z; Arienti F; Parmiani G; Ferrone S
Eur J Immunol; 1998 Sep; 28(9):2817-26. PubMed ID: 9754569
[TBL] [Abstract][Full Text] [Related]
17. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer.
Kaklamanis L; Leek R; Koukourakis M; Gatter KC; Harris AL
Cancer Res; 1995 Nov; 55(22):5191-4. PubMed ID: 7585572
[TBL] [Abstract][Full Text] [Related]
18. HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities.
Feinmesser M; Sulkes A; Morgenstern S; Sulkes J; Stern S; Okon E
J Clin Pathol; 2000 Apr; 53(4):286-91. PubMed ID: 10823125
[TBL] [Abstract][Full Text] [Related]
19. Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers.
Ryu KS; Lee YS; Kim BK; Park YG; Kim YW; Hur SY; Kim TE; Kim IK; Kim JW
Exp Mol Med; 2001 Sep; 33(3):136-44. PubMed ID: 11642549
[TBL] [Abstract][Full Text] [Related]
20. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas.
Feenstra M; Veltkamp M; van Kuik J; Wiertsema S; Slootweg P; van den Tweel J; de Weger R; Tilanus M
Tissue Antigens; 1999 Sep; 54(3):235-45. PubMed ID: 10519360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
